Acurx Pharmaceuticals, Inc. Cash and Restricted Cash
Acurx Pharmaceuticals, Inc. (ACXP) had Cash and Restricted Cash of $10.66 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.66M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.25M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.56M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.91M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $10.66M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $9.25M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $7.56M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $5.91M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $6.06M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $4.64M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $3.71M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $5.76M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $6.36M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $8.92M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $7.47M 10-K · filed 2026-03-12 |
| 2023-09-30 | $7.05M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $9.15M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $7.18M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $9.11M 10-K · filed 2025-03-17 |
| 2022-09-30 | $10.61M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $9.09M 10-Q · filed 2023-08-11 |
| 2022-03-31 | $11.08M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $12.96M 10-K · filed 2024-03-15 |
| 2021-09-30 | $14.46M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $17.10M 10-Q · filed 2022-08-12 |
| 2021-03-31 | $2.63M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $3.18M 10-K · filed 2023-03-15 |
| 2019-12-31 | $2.48M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |